In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B | Zendy

Caroline B. Moore | Zendy; Caroline M. Walls | Zendy; David W. Denning | Zendy

Open Access

In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B

Author(s) -

Caroline B. Moore,

Caroline M. Walls,

David W. Denning

Publication year - 2000

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.44.2.441-443.2000

Subject(s) - itraconazole , amphotericin b , triazole , in vitro , pharmacology , aspergillus , chemistry , fungi imperfecti , microbiology and biotechnology , antifungal , stereochemistry , medicine , biology , biochemistry , organic chemistry

The in vitro activity of BMS-207147 against 80 clinical isolates ofAspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in μg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to >16 μg/ml.Aspergillus fumigatus was significantly more susceptible to BMS-207147 (P < 0.05) thanA. terreus andA. flavus . No BMS-207147-resistantA. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, >8 μg/ml) isolates were. BMS-207147 is active againstAspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research